Phylogenetic analysis, structure modeling and docking study of HCV NS3 protease for the identification of potent inhibitors

被引:2
作者
Zia, Asad [1 ]
Abbasi, Sumra Wajid [2 ]
Ahmad, Shabeer [4 ]
Zia, Muhammad [1 ]
Raza, Abida [3 ]
机构
[1] Quaid I Azam Univ, Dept Biotechnol, Islamabad, Pakistan
[2] Quaid I Azam Univ, Dept Bioinformat, Islamabad, Pakistan
[3] Natl Inst Lasers & Optron, Islamabad, Pakistan
[4] Abasyn Univ, Dept Microbiol & Biotechnol, Peshawar, Pakistan
关键词
NS3; helicase; Sequencing; NS5B polymerase inhibitors; Homology modeling; Molecular docking; HEPATITIS-C-VIRUS; QMCF MD SIMULATION; NEIGHBOR-JOINING METHOD; SERINE-PROTEASE; RNA-POLYMERASE; MECHANISM; GENERATION; DISCOVERY; HYDRATION; PROTEINS;
D O I
10.1016/j.meegid.2018.01.026
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The nonstructural protein 3 (NS3) helicase of HCV is believed to be a plausible target for the identification and designing of potent antiviral drugs. NS3 protein is involved in a positive sense single-stranded viral replication as well as it also cleaves viral poly protein into diverse mature proteins at different time spans. Structural exploration of NS3 revealed that HCV helicase could also act as translocase. In order to identify potential inhibitors for HCV-3a, the current study has been designed. Serum samples from the Pakistani HCV positive patients were collected, sequenced and after purification included in the present study. Phylogenetic analysis on the samples clustered around it in the same group with those from India. Using homology modeling technique, we determined 3D structure of NS3 gene of HCV-3a and employed further in docking studies to discover potent inhibitor against it. As a result of docking Compound 1, with IC50 value of 0.015 and -14.4kcal/mol energy, ranked as a most pungent inhibitor among all the studied inhibitors. Compound 1 also exhibited good hydrogen bond interactions with the modeled protein. The finding of present study could be used as a lead in future to design an effective dual inhibitor against HCV-3a.
引用
收藏
页码:51 / 62
页数:12
相关论文
共 50 条
[21]   Design, Synthesis, and Evaluation of Oxygen-Containing Macrocyclic Peptidomimetics as Inhibitors of HCV NS3 Protease [J].
Velazquez, Francisco ;
Venkatraman, Srikanth ;
Blackman, Melissa ;
Pinto, Patrick ;
Bogen, Stephane ;
Sannigrahi, Mousumi ;
Chen, Kevin ;
Pichardo, John ;
Hart, Andrea ;
Tong, Xiao ;
Girijavallabhan, Viyyoor ;
Njoroge, F. George .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (03) :700-708
[22]   Molecular docking study of P4-Benzoxaborole-substituted ligands as inhibitors of HCV NS3/4A protease [J].
Wadood, Abdul ;
Riaz, Muhammad ;
Jamal, Syed Babar ;
Shah, Masaud ;
Lodhi, Muhammad Arif .
BIOINFORMATION, 2013, 9 (06) :309-314
[23]   In Silico Screening for Potent Inhibitors against the NS3/4A Protease of Hepatitis C Virus [J].
Meeprasert, Arthitaya ;
Rungrotmongkol, Thanyada ;
Li, Mai Suan ;
Hannongbua, Supot .
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (21) :3465-3477
[24]   Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups [J].
Venkatraman, Srikanth ;
Velazquez, Francisco ;
Wu, Wanli ;
Blackman, Melissa ;
Madison, Vincent ;
Njoroge, F. George .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (07) :2151-2155
[25]   Boceprevir, an NS3 Protease Inhibitor of HCV [J].
Berman, Kenneth ;
Kwo, Paul Y. .
CLINICS IN LIVER DISEASE, 2009, 13 (03) :429-+
[26]   Structural Analysis of Asunaprevir Resistance in HCV NS3/4A Protease [J].
Soumana, Djade I. ;
Ali, Akbar ;
Schiffer, Celia A. .
ACS CHEMICAL BIOLOGY, 2014, 9 (11) :2485-2490
[27]   Theoretical Study on Modified Boceprevir Compounds as NS3 Protease Inhibitors [J].
Saleh, Noha A. ;
Ezat, Ahmed A. ;
Elfiky, Abdo A. ;
Elshemey, Wael M. ;
Ibrahim, Medhat .
JOURNAL OF COMPUTATIONAL AND THEORETICAL NANOSCIENCE, 2015, 12 (03) :371-375
[28]   Human pegivirus (GB virus C) NS3 protease activity inhibits induction of the type I interferon response and is not inhibited by HCV NS3 protease inhibitors [J].
Chowdhury, Adnan Y. ;
Tavis, John E. ;
George, Sarah L. .
VIROLOGY, 2014, 456 :300-309
[29]   Treatment of HCV infection with the novel NS3/4A protease inhibitors [J].
De Luca, Andrea ;
Bianco, Claudia ;
Rossetti, Barbara .
CURRENT OPINION IN PHARMACOLOGY, 2014, 18 :9-17
[30]   Integrated in silico approach for discovering novel HCV NS3/4A protease inhibitors: virtual screening, docking, and dynamic simulation [J].
Zekri, Afaf ;
Ouassaf, Mebarka ;
Khan, Shafi Ullah ;
Rengasamy, Kannan R. R. ;
Alhatlani, Bader Y. .
CHEMICAL PAPERS, 2025, 79 (06) :3753-3772